Study on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best timing for surgery to treat a condition called a ventricular septal defect, which can occur after a heart attack (also known as a myocardial infarction). The goal is to find out when it is most effective to perform surgery on patients who develop this defect after experiencing a heart attack. The trial is currently looking for participants, specifically adults aged 18 and older who have had this type of heart defect and are planning to undergo surgery.
To be eligible for the trial, patients need to have had a heart attack that led to the defect and must agree to participate by signing consent forms. However, patients who are being treated with medications alone or who have defects not related to a heart attack cannot join. Those who participate can expect to be part of an important study that aims to improve treatment outcomes for people with this heart condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over eighteen years of age
- • Patients with post-myocardial infarction ventricular septal defect treated surgically
- • Patients who have signed the informed consent
- Exclusion Criteria:
- • Patients with post-infarction ventricular septal defect treated with medical/conservative therapy
- • Patients with ventricular septal defects not due to acute myocardial infarction
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Udine, , Italy
Varese, , Italy
Barcellona, , Spain
Patients applied
Trial Officials
Luca Di Marco, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported